



**Masterclass in Cardiac Amyloidosis:
Disease Spectrum, Diagnosis and Management**

March 13-15, 2026

Live Virtual Event

Program Director

Saurabh Malhotra, MD, MPH, FASNC

Friday, March 13, 2026 5 pm-7:30 pm ET

5:00 pm	Introduction, Program Goals and Logistics	Saurabh Malhotra, MD, MPH, FASNC
5:05 pm	#1. ASNC's role in amyloidosis education	Jamieson Bourque, MD, MHS, FASNC
Session 1: Disease and Pathogenesis: Moderator – Saurabh Malhotra, MD, MPH, FASNC		
5:10 pm – 5:40 pm	#2. Amyloid fibrils and amyloidogenesis	Jonathan Wall, PhD
5:40 pm – 6:10 pm	#3. Amyloidosis: The changing clinical landscape and evolving understanding of the disease	David Wolinsky, MD, MASNC
6:10 pm – 6:40 pm	#4. Should we screen for amyloidosis: When and how often?	Frederick Ruberg, MD
6:40 pm – 7:10 pm	#5. Non-cardiac manifestations: What to look for, where and how	Wael Jaber, MD, FASNC
7:10 pm	Summary and closing comments	Saurabh Malhotra, MD, MPH, FASNC

Saturday, March 14, 2026 10 am-3:45 pm ET

10:00 am	Introduction to Day 2	Saurabh Malhotra, MD, MPH, FASNC
----------	-----------------------	----------------------------------

Session 2: Diagnostic Techniques and Pitfalls: A Case-Based Discussion: Moderator – David Wolinsky, MD, MASNC

10:05 am – 10:35 am	#6. Multimodality imaging strengthens the suspicion of amyloidosis	Cesia Gallegos-Kattán MD, MHS FASNC
10:35 am – 11:05am	#7. Nuclear scintigraphy with bone avid tracers: Improving study quality and interpretation	Saurabh Malhotra, MD, MPH, FASNC
11:05 am – 11:35 am	#8. A case-based journey through best practices and common mistakes	Cigdem Akincioglu, MD, FASNC
11:35 am – 12:05 pm	#9. Novel tracers and their potential role in diagnosis and disease monitoring	Sharmila Dorbala, MD, MPH, MASNC
12:05 pm – 12:35 pm	#10. Amyloid mutations and role of genetic testing	Ashutosh Wechalekar, MBBS, MD
12:35 pm	Final Comments	Faculty

Break

Session 3: Challenges in Diagnosis and Management of ATTR: Moderator – Frederick Ruberg, MD

1:00 pm – 1:45 pm	#11. Role of tissue diagnosis and challenges	Angela Dispensieri, MD
1:45 pm – 2:15 pm	#12. The more the merrier? Considerations for choice of therapy	Mathew Maurer, MD
2:15 pm – 2:45 pm	#13. Diagnostic and treatment challenges in underrepresented populations (age, ethnicity)	Kevin Alexander, MD
2:45 pm – 3:15 pm	#14. Opportunities and approach to starting an amyloid program in the community	Katherine Lee Chuy, MD



3:15 pm – 3:45pm	#15. Patient perspective and increasing awareness	Michael Lane, Amyloid Patient
3:45 pm	Closing Comments	Saurabh Malhotra, MD, MPH, FASNC
Sunday, March 15, 2026 10 am – 12:45pm ET		
10:00 am – 10:05 am	Introduction to Day 3	Saurabh Malhotra, MD, MPH, FASNC
Session 4: Practical Concepts for Treatment of Amyloidosis: Moderator – Saurabh Malhotra, MD, MPH, FASNC		
10:05 am – 10:30 am	#16. Application of prognostic markers in AL and ATTR amyloidosis	Andrew Staron, MD
10:30 am – 11:00 am	#17. Amyloid polyneuropathy for the non-neurologist: Diagnosis and management	Sasha Zivkovic, MD, PhD
11:00 am – 11:30 am	#18. Updates in management of heart failure in patients with amyloidosis	Ahmad Masri, MD, MS
11:30 am – 12:00 pm	#19. Monitoring of disease: Regression or progression?	Brett Sperry, MD, FASNC
12:00 pm – 12:30 pm	#20. Unanswered questions across the spectrum of care	Prem Soman, MD, PhD, MASNC
12:30 pm	Q&A and final comments and adjourn	Saurabh Malhotra, MD, MPH, FASNC